Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flinn

Showing results (911-920 of 1,038) with videos related to

Pageof 104
Sort By:
Blood|October 17, 2015
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemiaSusan M O'Brien, Nicole Lamanna, Thomas J Kipps, et al.
Cancer Discovery|November 6, 2023
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin LymphomaJennifer A Woyach, Deborah M Stephens, Ian W Flinn, et al.
Blood|May 5, 2017
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphomaJohn Kuruvilla, Michael Savona, Rachid Baz, et al.
The Lancet. Oncology|December 8, 2018
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Research Square|February 13, 2023
Optimising the yield from bronchoalveolar lavage on human participants in infectious disease immunology researchJane Alexandra Shaw, Maynard Meiring, Devon Allies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2024
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, Sagar Lonial, Amanda Cashen, et al.
Scientific Reports|May 31, 2023
Optimising the yield from bronchoalveolar lavage on human participants in infectious disease immunology researchJane Alexandra Shaw, Maynard Meiring, Devon Allies, et al.
Scientific Reports|July 12, 2026
Diagnostic accuracy of CRP and myeloperoxidase as a 2-marker biosignature for the diagnosis of symptomatic TBLesego Rantho, Bih H Chendi, Megan-Lee Burger, et al.
British Journal of Haematology|March 18, 2020
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphomaNathan H Fowler, Loretta Nastoupil, Sven De Vos, et al.
Haematologica|August 16, 2019
A cross-trial comparison of single-agent ibrutinib <i>versus</i> chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphomaAlessandra Tedeschi, Richard Greil, Fatih Demirkan, et al.
Pageof 104

Showing results (911-920 of 1,038) with videos related to

Sort By:
Pageof 104
Blood|October 17, 2015
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemiaSusan M O'Brien, Nicole Lamanna, Thomas J Kipps, et al.
Cancer Discovery|November 6, 2023
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin LymphomaJennifer A Woyach, Deborah M Stephens, Ian W Flinn, et al.
Blood|May 5, 2017
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphomaJohn Kuruvilla, Michael Savona, Rachid Baz, et al.
The Lancet. Oncology|December 8, 2018
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Research Square|February 13, 2023
Optimising the yield from bronchoalveolar lavage on human participants in infectious disease immunology researchJane Alexandra Shaw, Maynard Meiring, Devon Allies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2024
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, Sagar Lonial, Amanda Cashen, et al.
Scientific Reports|May 31, 2023
Optimising the yield from bronchoalveolar lavage on human participants in infectious disease immunology researchJane Alexandra Shaw, Maynard Meiring, Devon Allies, et al.
Scientific Reports|July 12, 2026
Diagnostic accuracy of CRP and myeloperoxidase as a 2-marker biosignature for the diagnosis of symptomatic TBLesego Rantho, Bih H Chendi, Megan-Lee Burger, et al.
British Journal of Haematology|March 18, 2020
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphomaNathan H Fowler, Loretta Nastoupil, Sven De Vos, et al.
Haematologica|August 16, 2019
A cross-trial comparison of single-agent ibrutinib <i>versus</i> chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphomaAlessandra Tedeschi, Richard Greil, Fatih Demirkan, et al.
Pageof 104